JP2020525436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525436A5 JP2020525436A5 JP2019570906A JP2019570906A JP2020525436A5 JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5 JP 2019570906 A JP2019570906 A JP 2019570906A JP 2019570906 A JP2019570906 A JP 2019570906A JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- compound
- dosage form
- gastric resistance
- resistance controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023147484A JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523204P | 2017-06-21 | 2017-06-21 | |
| US62/523,204 | 2017-06-21 | ||
| PCT/US2018/038853 WO2018237207A1 (en) | 2017-06-21 | 2018-06-21 | GESTRO-RESISTANT ORAL DOSAGE FORMS WITH CONTROLLED RELEASE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Division JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525436A JP2020525436A (ja) | 2020-08-27 |
| JP2020525436A5 true JP2020525436A5 (https=) | 2021-07-29 |
Family
ID=62904624
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570906A Pending JP2020525436A (ja) | 2017-06-21 | 2018-06-21 | 胃耐性制御放出経口剤形 |
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11464744B2 (https=) |
| EP (1) | EP3641732A1 (https=) |
| JP (3) | JP2020525436A (https=) |
| CN (1) | CN111511353A (https=) |
| AU (2) | AU2018290287B2 (https=) |
| BR (1) | BR112019027398A2 (https=) |
| CA (1) | CA3067031A1 (https=) |
| CL (1) | CL2019003743A1 (https=) |
| CO (1) | CO2019014496A2 (https=) |
| IL (3) | IL319156A (https=) |
| MX (1) | MX2023002994A (https=) |
| NZ (1) | NZ760127A (https=) |
| PE (1) | PE20200732A1 (https=) |
| UA (1) | UA127349C2 (https=) |
| WO (1) | WO2018237207A1 (https=) |
| ZA (1) | ZA202409847B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| EP3840835A1 (en) | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| EP4479049B1 (en) | 2022-02-14 | 2025-12-17 | Minerva Neurosciences, Inc. | Use of roluperidone in preventing relapse in schizophrenia patients |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3888340T2 (de) | 1988-01-21 | 1994-06-30 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. |
| ZA908641B (en) | 1989-10-27 | 1992-06-24 | Du Pont | (n-phthalimidoalkyl)piperidines |
| CA2134077C (en) | 1992-04-23 | 2002-05-21 | Thaddeus R. Nieduzak | 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy |
| US7166617B2 (en) | 2000-02-29 | 2007-01-23 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| ATE361060T1 (de) | 2000-09-29 | 2007-05-15 | Solvay Pharm Bv | Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung |
| ES2405404T3 (es) | 2003-10-29 | 2013-05-31 | Wyeth Llc | Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| PE20061490A1 (es) | 2005-06-06 | 2007-02-09 | Merck Sharp & Dohme | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 |
| US20090088449A1 (en) | 2006-02-07 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | 4-acylaminopyridine derivative mediated neurogenesis |
| CA2569776A1 (en) | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| KR20080089279A (ko) | 2007-03-30 | 2008-10-06 | 미쓰비시 타나베 파마 코퍼레이션 | 우울증의 예방 및/또는 치료제 |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| EP2246331A1 (en) | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selective NMDA-receptor antagonists |
| ES2530049T3 (es) | 2009-05-18 | 2015-02-26 | Sigmoid Pharma Limited | Composición que comprende gotas de aceite |
| AR081935A1 (es) | 2010-06-16 | 2012-10-31 | Teijin Pharma Ltd | Tableta con nucleo recubierto de liberacion controlada |
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| TWI520949B (zh) | 2010-07-20 | 2016-02-11 | 錫蘭尼克藥物有限公司 | 使用環醯胺衍生物治療σ受體介導之病症的方法 |
| RS64819B1 (sr) | 2010-07-20 | 2023-12-29 | Minerva Neurosciences Inc | Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma |
| US20120040008A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| EP2468264A1 (en) * | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| KR20140045925A (ko) | 2011-03-17 | 2014-04-17 | 루핀 리미티드 | 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물 |
| CA2845228C (en) * | 2011-08-16 | 2021-08-10 | Baker Idi Heart & Diabetes Institute Holdings Limited | Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds |
| AU2014239883B2 (en) * | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| CN104586771B (zh) * | 2013-10-30 | 2018-01-16 | 广州朗圣药业有限公司 | 一种盐酸坦洛新缓释微丸制剂 |
| MA39987A (fr) * | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| EP3144308B1 (en) | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| KR102425303B1 (ko) * | 2014-08-13 | 2022-07-25 | 세다르스-신나이 메디칼 센터 | 항-메탄생성 조성물 및 그것의 용도 |
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| WO2017066134A1 (en) * | 2015-10-16 | 2017-04-20 | Merck Sharp & Dohme Corp. | Processes for preparing formulations for gastrointestinal-targeted therapies |
| TWI820001B (zh) | 2016-05-25 | 2023-11-01 | 日商田邊三菱製藥股份有限公司 | 醫藥組成物的用於製造非思覺失調症病患之負性症狀治療劑的用途 |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| EP3840835A1 (en) | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| WO2020264486A1 (en) | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
| EP4479049B1 (en) | 2022-02-14 | 2025-12-17 | Minerva Neurosciences, Inc. | Use of roluperidone in preventing relapse in schizophrenia patients |
-
2018
- 2018-06-21 IL IL319156A patent/IL319156A/en unknown
- 2018-06-21 CN CN201880054407.9A patent/CN111511353A/zh active Pending
- 2018-06-21 PE PE2019002573A patent/PE20200732A1/es unknown
- 2018-06-21 CA CA3067031A patent/CA3067031A1/en active Pending
- 2018-06-21 UA UAA202000290A patent/UA127349C2/uk unknown
- 2018-06-21 JP JP2019570906A patent/JP2020525436A/ja active Pending
- 2018-06-21 IL IL271606A patent/IL271606B2/en unknown
- 2018-06-21 EP EP18740435.5A patent/EP3641732A1/en active Pending
- 2018-06-21 AU AU2018290287A patent/AU2018290287B2/en active Active
- 2018-06-21 WO PCT/US2018/038853 patent/WO2018237207A1/en not_active Ceased
- 2018-06-21 NZ NZ760127A patent/NZ760127A/en unknown
- 2018-06-21 US US16/015,151 patent/US11464744B2/en active Active
- 2018-06-21 BR BR112019027398-0A patent/BR112019027398A2/pt active IP Right Grant
- 2018-06-21 IL IL308650A patent/IL308650B2/en unknown
-
2019
- 2019-12-18 CL CL2019003743A patent/CL2019003743A1/es unknown
- 2019-12-18 MX MX2023002994A patent/MX2023002994A/es unknown
- 2019-12-20 CO CONC2019/0014496A patent/CO2019014496A2/es unknown
-
2022
- 2022-06-15 US US17/841,284 patent/US12048768B2/en active Active
-
2023
- 2023-09-12 JP JP2023147484A patent/JP2023175778A/ja active Pending
-
2024
- 2024-06-10 US US18/738,782 patent/US20250009665A1/en active Pending
- 2024-09-13 AU AU2024219717A patent/AU2024219717A1/en active Pending
- 2024-12-19 ZA ZA2024/09847A patent/ZA202409847B/en unknown
-
2025
- 2025-06-17 JP JP2025101290A patent/JP2025134828A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525436A5 (https=) | ||
| JP6084161B2 (ja) | ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤 | |
| FI117961B (fi) | Nopeasti vaikutuksen aloittava formulaatio | |
| CN110035757A (zh) | 一种奥拉帕尼口服缓控释药物组合物及其用途 | |
| CN105142618A (zh) | 提供药理及临床效应的莫沙必利每日单次施用缓释制剂 | |
| JP2014501267A (ja) | メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法 | |
| JP2015510916A5 (https=) | ||
| JP2013529665A5 (https=) | ||
| WO2014029953A1 (en) | Hot melt extruded (hme) pharmaceutical composition of cinacalcet | |
| AU2014279743B2 (en) | Modified release formulation | |
| EP2841061A1 (en) | Methods for treating cardiovascular disorder | |
| CN101431992A (zh) | 包含尼美舒利的新型低剂量药物组合物及其制备和用途 | |
| JP2016530238A5 (https=) | ||
| JP2023026417A (ja) | フマル酸ジメチルを含有する腸溶性錠剤 | |
| JP2010538062A5 (https=) | ||
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| JP2015120758A5 (https=) | ||
| EP3326653A1 (en) | Delayed release dosage forms comprising dimethyl fumarate | |
| WO2022138717A1 (ja) | 経口固形製剤 | |
| JP6854162B2 (ja) | 錠剤 | |
| JP6815109B2 (ja) | デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物 | |
| CA2854612C (en) | Delivery systems for improving oral bioavailability of fenobam, its hydrates, and salts | |
| EP3439638A1 (en) | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof | |
| EP3796904A1 (en) | Sustained release acemetacin compositions | |
| EP2236159A2 (en) | Modified release dimebolin compositions |